共 50 条
- [31] A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancerNature Communications, 13Biyun WangTao SunYannan ZhaoShusen WangJian ZhangZhonghua WangYue-E TengLi CaiMin YanXiaojia WangZefei JiangYueyin PanJianfeng LuoZhimin ShaoJiong WuXiaomao GuoXichun Hu
- [32] Capecitabine Combined With Docetaxel Versus Vinorelbine Followed by Capecitabine Maintenance Medication for First-Line Treatment of Patients With Advanced Breast Cancer: Phase 3 Randomized TrialCANCER, 2015, 121 (19) : 3412 - 3421Wang, JiayuXu, BingheYuan, PengMa, FeiLi, QingZhang, PinCai, RuigangFan, YingLuo, YangLi, Qiao
- [33] Clinical effects of prior anthracycline or taxane use on eribulin as first-line treatment for HER± locally recurrent or metastatic breast cancer (BC): Results from 2 phase 2, multicenter, single-arm studies.JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (26)Gluck, StefanO'Shaughnessy, JoyceMcIntyre, KristiSchwartzberg, Lee StevenWilks, SharonHuggins-Puhalla, Shannon LeighBerrak, ErhanSong, James X.Cox, DavidVandat, Linda T.
- [34] A randomized multi-center phase II trial of capecitabine (X) versus S-1 (S) as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancerANNALS OF ONCOLOGY, 2007, 18 : VII25 - VII25Kang, Y.Lee, J.Min, Y.Lee, K.Zang, D.Ryoo, B.Kim, J.Park, S.Kang, W.Shin, D.
- [35] A randomized multi-center phase II trial of capecitabine (X) versus S-1 (S) as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancerJOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)Kang, Y.Lee, J.Min, Y.Lee, K.Zang, D.Ryoo, B.Kim, J.Park, S.Kang, W.Shin, D.
- [36] HARMONi-3: A randomized, controlled, multiregional Phase 3 study of ivonescimab combined with chemotherapy versus pembrolizumab combined with chemotherapy for the first-line treatment of metastatic squamous non-small cell lung cancerMOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)Riess, JonathanLu, ShunNaidoo, JarushkaKuruvilla, SaraHung, AnnieKhaled, AhmedDoroshow, Deborah
- [37] Nab-paclitaxel plus S-1 versus oxaliplatin plus S-1 as first-line treatment in advanced gastric cancer: results of a multicenter, randomized, phase III trial (GAPSO study)THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14Dai, Yu-HongYu, Xiong-JieXu, Hui-TingZhuang, LiangZhang, Ming-ShengZou, Yan-MeiFu, QiangQiu, HongYuan, Xiang-Lin
- [38] Randomised phase 3 study of S-1 versus capecitabine, with bevacizumab optional in both arms, in the first-line treatment of metastatic colorectal cancer (mCRC), the SALTO study of the Dutch Colorectal Cancer GroupEUROPEAN JOURNAL OF CANCER, 2017, 72 : S5 - S5Kwakman, J. J. M.Simkens, L. H. J.Van Rooijen, J. M.de Wouw, A. J. VanLoosveld, O. J. L.Creemers, G. J. M.Hendriks, M. P.Los, M.Van Alphen, R. J.Polee, M. B.Muller, E. W.Van der Velden, A. M. T.Van Voorthuizen, T.Koopman, M.Mol, L.Van Werkhoven, E.Punt, C. J. A.
- [39] S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trialBMC CANCER, 2014, 14Kim, Seung TaeHong, Yong SangLim, Ho YeongLee, JeeyunKim, Tae WonKim, Kyu-PyoKim, Sun YoungBaek, Ji YeonKim, Jee HyunLee, Keun-WookChung, Ik-JooCho, Sang-HeeLee, Kyung HeeShin, Sang JoonKang, Hye JinShin, Dong BokLee, Jae WonJo, Sook JungPark, Young Suk
- [40] S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trialBMC Cancer, 14Seung Tae KimYong Sang HongHo Yeong LimJeeyun LeeTae Won KimKyu-Pyo KimSun Young KimJi Yeon BaekJee Hyun KimKeun-Wook LeeIk-Joo ChungSang-Hee ChoKyung Hee LeeSang Joon ShinHye Jin KangDong Bok ShinJae Won LeeSook Jung JoYoung Suk Park